VeinDirectory.org

 

 
 
 
 

VeinDirectory - "The Know"

"The Know" is an informational resource concerning vein treatment options. It contains valuable information for prospective patients, physicians as well as those in the vein treatment industry. We will be regularly posting educational articles, video logs and other pertinent information. We encourage your feedback and welcome any suggestions that you feel may improve the blog.

January 2011 Blog Archive

Friday, January 28, 2011
VENOSAN INTRODUCES VENOHOOKS
Venosan North America are pleased to introduce the VENOHOOKS™ comprehensive range of instruments for vein surgery including instruments similar to those designed by eminent European doctors including Mueller, Varady, Ramelet and the original hook designed by Oesch®. All the instruments are made in the USA with the exception of the original Oesch hook and stripper.

Venosan North America’s president Robert Spalding explained that there are several hooks on the market with distal ends similar to the original hooks but what makes VENOHOOKS different are the handles. “Arguably, the handle is as important as the hook”, explains Spalding. “For example the handle of the Ramelet type hook is designed to roll eloquently between finger and thumb to allow a dissecting and hooking motion without changing instrument and, most important, a minimal size incision. The handle of the Mueller type hook should fit nicely in the palm of the hand to allow a firm grip. The Varady type hook is designed to work for both right and left handed doctors and can be deftly turned to be a hook or a dissector. The Oesch hook has a solid, wide handle that gives its user a steady, firm grip while locating and removing a vein. We think doctors will really welcome VENOHOOKS” Spalding adds.

Hooks are available in left or right handed models (except of course Varady type). Call 800 432 5347.

Friday, January 28, 2011
Vascular Solutions introduces the SmartNeedle Vascular Access System
Vascular Solutions, Inc. recently acquired the SmartNeedle® Vascular Access system. The SmartNeedle system consists of a hand-held monitor and one-time use needles designed to provide auditory ultrasound guided access to arteries and veins during catheterization procedures.

The SmartNeedle monitor is a re-usable, hand-held device that transmits a continuous wave Doppler signal, providing continuous auditory feedback to help locate and access the artery or vein quickly and with confidence. If desired, the monitor can be covered with a disposable sterile bag for use in the sterile field. Sterile, single-use SmartNeedles range from 18G to 24G, with bare tip and sheathed IV options. Bare-tipped needles are available in 18G, 20G and 22G sizes, and consist of a detachable Doppler probe that is housed within the lumen of a standard sized introducer needle. IV sheathed needles, used when attempting to access a vessel with the intent of leaving a small catheter in place, are available in 20G, 22G, 24G and 26G sizes.

Acquired by Vascular Solutions from Escalon Medical in May 2010, the SmartNeedle system was formerly known as the pdAccess Doppler guided needle access system. Moving forward, Vascular Solutions will use solely the name SmartNeedle. SmartNeedle products are available in the United States and Europe.

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of over 50 products in three categories: catheter products, hemostat products and vein products.



Friday, January 28, 2011
SIGVARIS Announces New Shade in Popular Medical Compression Hosiery Line
Sales Soar as Style-Savvy Women Go Nude in SIGVARIS Soft Opaque Graduated Compression Hosiery
SIGVARIS, the global leader in medical compression hosiery and committed DVT prevention advocate, is pleased to announce a new shade in one of its most popular medical compression hosiery lines.

Women everywhere have fallen in love with the microfiber softness and comfort of Soft Opaque. Since the product launched in September, the demand for this product has been astounding. SIGVARIS is now manufacturing a skin-toned shade to keep up with the demands of customers that love this new product.

The nude shade, which just launched, is already flying off the shelves. The nude shade is perfect for masking problem areas women don’t want others to see. Soft Opaque is also available in midnight blue, black, espresso and graphite shades. Styles include calf-length, thigh-highs and pantyhose. Soft Opaque is popular because it has the luxurious look and feel of products found at high-end department stores with all the benefits of medical compression hosiery.

SIGVARIS medical compression hosiery promotes leg health and is universally recommended for both the surgical and non-surgical treatment of venous disorders. The product may also be worn to alleviate heavy, tired legs for women during pregnancy.

About SIGVARIS
SIGVARIS® North America is part of an internationally active medical device group headquartered in Winterthur, Switzerland that focuses on the development, production and distribution of medical graduated compression garments, including hosiery and socks. With distribution in more than 50 countries on six continents, SIGVARIS, is recognized as a global industry leader in the area of compression therapy for the management of chronic venous insufficiency and venous disorders. SIGVARIS’ US manufacturing plant is located in Peachtree City, GA. SIGVARIS is a committed DVT prevention advocate. In addition to medical products, SIGVARIS also manufactures lifestyle and sports products based on its expertise in graduated compression therapy.

SIGVARIS, LIFE FOR LEGS and the leg icon are registered trademarks of Ganzoni & Cie AG, St.Gallen/Switzerland and in many countries worldwide.


Friday, January 28, 2011
SIGVARIS Graduated Compression Socks Keep World Famous Soccer Player, Ronaldo, in the game
SIGVARIS is a proud manufacturer of the “famous socks” that have kept Soccer Star Ronaldo Luís Nazário de Lima in the game by improving circulation and alleviating pain!

SIGVARIS, the global leader of graduated compression garments and committed DVT prevention advocate, is proud to announce that superstar soccer player Ronaldo from Brazil has discovered the benefits of wearing SIGVARIS graduated compression socks during and after soccer games.

Ronaldo, who suffered from a left calf injury, finds the socks to be a crucial part of his team uniform. Ronaldo was diagnosed with a venous insufficiency problem in his left calf that could have ended his career. However, the doctor recommended SIGVARIS socks to help alleviate pain in the calf region allowing him to play.

Ronaldo, who has been named a FIFA Player of the Year three times, is not the only athlete that knows firsthand the benefits of wearing true graduated compression. Many professional athletes worldwide are using compression stockings during and after performance events to improve their results.

By compressing the leg and calf with graduated external pressure, blood flow in the veins is improved, which increases circulation and oxygen to the muscle tissue. This helps to flush out the lactic acids built up in the legs during exercise, relieving tired, aching legs and exercise-induced muscle soreness.

Endorsers of SIGVARIS’ Active Therapy Socks include Michael Turner (Atlanta Falcons running back), Joseph Addai (Indianapolis Colts running back), David O’Meara (The One Mile Runner) and LPGA’s Brittany Lincicome.

SIGVARIS, through the Athletic Recovery line of socks, has established partnerships with established sports organizations in North America, including Road Runner’s Club of America (RRCA), USProTri, Southern Crescent Cycling Club and Cross Country Canada (CCC-skiing). SIGVARIS is supplying socks to the Atlanta Falcons and Indianapolis Colts NFL football teams for practice, recovery and travel for the 2010 and 2011 football seasons. New Jersey NETS basketball is the latest addition to SIGVARIS’ sports partnerships.

About SIGVARIS

SIGVARIS® North America is part of an internationally active medical device group headquartered in Winterthur, Switzerland that focuses on the development, production and distribution of medical compression garments, including hosiery and socks. With distribution in more than 50 countries on six continents, SIGVARIS is recognized as a global industry leader in the area of compression therapy for the management of venous disorders. Our US manufacturing plant is located in Peachtree City, GA.
Friday, January 28, 2011
Carl Landry Official Endorser of SIGVARIS Athletic Socks
SIGVARIS is pleased to announce that Carl Landry, Sacramento forward, has become a fan of SIGVARIS’ Active Therapy Line prompting him to become an official endorser of SIGVARIS’ athletic socks.

“It’s exciting for SIGVARIS that professional athletes worldwide have seen for themselves the value of wearing true graduated compression,” says Jason Kern, product manager of SIGVARIS North America. “It’s rewarding to see high profile players like Carl Landry, Soccer’s Ronaldo Luís Nazário de Lima, Joseph Addai (running back for the Indianapolis Colts) and Michael Turner (running back for the Atlanta Falcons) endorsing our socks. We are thrilled that we could use what we have learned by being the global leader in medical compression therapy to help athletes.”

The use of compression wear is a growing trend in athletics. Wearing true graduated compression, compression that is tightest at the ankle, during and after exercise or competition can help flush out lactic acid and provide symptomatic relief of delayed onset leg muscle soreness. SIGVARIS manufactures both a Performance Sock and an Athletic Recovery Sock to help athletes peak their performance and speed up their recovery time!

“After 40-plus minutes against some of the top athletes in the world, nothing feels better on the long ride home than my SIGVARIS Athletic Recovery socks,” Landry says. “I have used similar products in the past, but they didn't help my legs after a game like these do. I am excited to be partnering with SIGVARIS because I know other athletes that try these socks are going to experience great results."

About Carl Landry
Carl Landry began his career as a basketball player for Purdue where he was a 4-Time BIG Ten Player of the Week and led the Boilermakers to the second round of the 2007 NCAA Tournament. He was selected by the Houston Rockets in the 2007 NBA draft and was later traded to the Sacramento Kings.

About SIGVARIS
SIGVARIS® North America is part of an internationally active medical device group headquartered in Winterthur, Switzerland that focuses on the development, production and distribution of medical graduated compression garments, including hosiery and socks. With distribution in more than 50 countries on six continents, SIGVARIS, is recognized as a global industry leader in the area of compression therapy for the management of chronic venous insufficiency and venous disorders. SIGVARIS’ US manufacturing plant is located in Peachtree City, GA. SIGVARIS is a committed DVT prevention advocate. In addition to medical products, SIGVARIS also manufactures lifestyle and sports products based on its expertise in graduated compression therapy.
SIGVARIS, LIFE FOR LEGS and the leg icon are registered trademarks of Ganzoni & Cie AG, St.Gallen/Switzerland and in many countries worldwide.

SIGVARIS® develops medical compression hosiery and socks, and is a global leader in compression therapy products that treat venous disorders like varicose veins, chronic vein insufficiency and deep vein thrombosis. www.sigvarisusa.com


Friday, January 28, 2011
medi USA Wins iF Award 2011 for Product Design
medi has received the iF product design award 2011 for its compression garment "mediven for men" from the International Forum Design). The sock, which was designed especially for men, impressed the judges in the evaluation criteria of finish, functionality and choice of materials.

Over 2,750 product nominations from 43 nations in 16 categories were submitted for this year's award. mediven for men was awarded the prestigious prize in the category medicine / health + care.

Since 1953 the iF product design award has been considered the hallmark accolade for outstanding design performance and reliability. The iF Label is awarded annually by international experts.

The appearance of the men’s knee sock with its business ribbed design and discreet choice of colours impressed the expert jury. mediven for men is also medically effective, and is used for early to moderate venous diseases as well as tired, heavy or swollen legs. To aid comfort and promote compliance mediven for men is shaped to the anatomy of men’s feet; the socks are left and right specific and are marked accordingly.

For more information, please call 800-633-6334

Friday, January 28, 2011
Established Vein Center Looking to Expand
Eraser’s Body Enhancement Centers of Florida, an established Vein and Advanced Cosmetics practice with two current locations, is looking to partner with an experienced physician to expand its business.

Eraser’s currently has two fully staffed offices (R.V.T., R.N.s, Billing Specialist, Estheticians) in Lakewood Ranch and Sun City, FL, just south of Tampa Bay. The facilities are ICAVL Accredited Vascular Laboratories and are equipped with CoolTouch Lyra and Aura Lasers, surgical instruments, liposuction equipment and a CoolLipo Laser.

Eraser’s founder and Medical Director, John V. Dunne, M.D., F.A.C.S, has over 50 years of experience in vein care. Stated Dr. Dunne, “We are in a unique position to expand our business, and are interested in speaking with physicians who are committed to excellence and helping us realize our potential. We have two terrific locations in sunny Florida, which adds excellent quality of life in addition to an opportunity for professional fulfillment.” Please contact Maleta, Administrator, at 941-704-6546 for more information.


Friday, January 28, 2011
Renowned Expert from Nationally-Recognized Medical Center Writes Patient’s Reference Guide on Venous Disease
Venous disease affects 50-80 million people in the United States and translates to over $1 billion dollars in lost employee productivity. After all, how can you stand or sit at work with unhealthy legs, poor circulation, or pressure on the nerves?

Varicose Veins…A Patient’s Reference is the first reference guide developed specifically to enhance a patient’s understanding of the causes, symptoms and treatment options for venous disorders. It is written for potential vein patients in a language they can understand and provides insight that they can apply on their first visit with the doctor of their choice. The content of the book encompasses all treatments of venous disease in various stages, with a variety of medical treatment options for various types and stages of venous disease.

Take the first step in regaining quality of life for yourself or a loved one by purchasing Varicose Veins…A Patient’s Reference, and seeking treatment from a trained physician who specializes in the treatment of venous disease in your area. Order your copy today by contacting the publisher at (877) 613-2665 or publishing@e-booktime.com.

Readers who do not live in Arizona, New Mexico or Texas, but are interested in visiting The Center for Venous Disease, our doctors offer a Fly-In and Fly-Out program at any of our CVD offices located in Arizona, New Mexico, and Texas. For more information on Center for Venous Disease, please call (623) 234-2542.

###

ABOUT THE CENTER FOR VENOUS DISEASE
The Center for Venous Disease (CVD) was established with the patient in mind and a singular mission: “Treat your symptoms and touch your Heart.” CVD is focused on a TOTAL VEIN CARE philosophy utilizing state-of-the-art technology with Board Certified Doctors. CVD’s Medical Directors are double- or triple-board-certified, including Phlebology (vein specialty), and utilize only FDA-approved drugs and FDA-cleared devices. CVD is a nationally recognized training facility for the VNUS Closure™ procedure for varicose vein treatment, and is the highest volume vein treatment center in the Southwest United States. This expertise sets CVD apart from other offices or hospitals who have added vein care to an existing practice that is focused on other medical conditions or specialties. For more information on Center for Venous Disease, please call (623) 234-2542.


Friday, January 28, 2011
New Toolkit Provides a Practical Overview Guide on VTE for Health Professionals
The Vascular Disease Foundation’s Venous Disease Coalition announced the launch of its new VTE Toolkit, A Practical Overview for Health Professionals. This toolkit was developed by the Venous Disease Coalition (VDC) and may be accessed online at www.venousdiseasecoalition.org/vte-toolkit.

The VTE Toolkit provides some of the key concepts about venous thromboembolism (VTE) and anticoagulant management. VTE is a common, potentially life-threatening, but treatable and generally preventable disorder that includes two related conditions, deep vein thrombosis (DVT) and pulmonary embolism (PE). This useful resource may be accessed for personal learning as well as educational activities with groups. The content of the toolkit has been carefully selected to reflect the essential current, evidence-based knowledge in the area of VTE.

The Toolkit is a series of 12 PowerPoint slide presentations that may be used separately or as a group. Each chapter can be used in its current form or modified to meet the educational needs of a specific audience or act as a supplement to presenters’ existing slides to complement a presentation. The slides are available in PowerPoint (Office 7-PPTX and Office 97-2003-PPT) and PDF formats.

“The VTE Toolkit was designed to be a “living resource”, said Dr. Bill Geerts, VDC Steering Committee member and chair of the VDC science committee. “We welcome feedback on the content and encourage users to send us material that can be used to supplement or replace some of the slides and thereby to enhance the quality of this resource.”

The VTE Toolkit is a free resource that was created by the VDC. The toolkit is made possible in part through funding from Eisai, Inc.

About the Venous Disease Coalition
The Venous Disease Coalition (VDC) promotes the urgent need to make venous thromboembolism or “VTE” a major U.S. public health priority. The VDC is an alliance of leading health professional societies and patient advocacy groups that have united around a common goal: to improve the survival rates and quality of life for individuals with, or at risk for, venous disease. It is a division of the Vascular Disease Foundation, a national, not-for-profit section 501(c)(3) organization and is supported by the following national sponsors: Eisai Inc., BSN Jobst, AngioDynamics, BioMedix, Cook Medical and Juzo.


Friday, January 28, 2011
HK Surgical Introduces New CVT Tubing for use with Klein Infiltration Pump
HK Surgical is pleased to announce the release of its new CVT Tubing – a new single-spike, infiltration tubing for use with the Klein Infiltration Pump in your vein ablation procedures to improve the infiltration experience.

Used in conjunction with HK Surgical’s Super Absorbent OR Table Pad, which holds over 1,000ml of fluid and is ideal for keeping your patients dry during the procedure (with only 1 pad needed per procedure), these products work together to provide the best experience for you and your patients.

To learn more about these products, please come by our booth #20 at the AVF Annual Meeting in San Diego, February 23-26, or call us at (800) 909-0060.

###

About HK Surgical
HK Surgical is dedicated to our commitment of providing the BEST products with the BEST customer service through continuous improvement efforts and product development. HK Surgical is a recognized leader in the development, distribution and marketing of superior liposuction and vein ablation equipment and supplies. HK Surgical markets a complete line of products including, aspiration and infiltration equipment, cannulas, compression garments and disposable items. HK Surgical is the exclusive distributor of the Monty Cannula and patented Super Absorbent Pad.


Friday, January 28, 2011
GloriaMed Group of Lake Como, Italy announces their 85th year in business
Celebrate our 85th Birthday with Gloria Med USA! GloriaMed began manufacturing compression stockings in 1926 and today continues the quality and traditions handed down through the generations. Look for special offers from GloriaMed in 2011 as we celebrate this milestone and continue to build our brand in the United States.
GloriaMed medical compression stockings are offered in 20-30 mm Hg and 30-40 mm Hg, consisting of a Micro line, Soft line and Comfort line, which is made with cotton. Our stockings and socks are available for men and women in a variety of styles, sizes and colors using the highest manufacturing standards, and are competitively priced.

We look forward to seeing you at upcoming meetings in 2011. For more information, please contact Gloria Med USA at 877-390-5347

Friday, January 28, 2011
Covidien Announces New Evidence that Demonstrates Clinical Efficacy of VNUS ClosureFAST Catheter
Multicenter Study Results Presented at 37th Annual VEITH Symposium

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter study using the VNUS ClosureFAST(TM) catheter, demonstrated clinical efficacy and improvement in quality of life for patients. The ClosureFAST catheter is an endovenous radiofrequency (RF) ablation catheter designed to heat and close diseased veins, the major underlying cause of varicose veins.

The results were presented at the American College of Phlebology's 24th Annual Congress in Orlando, Florida on November 5, and here today at the 37th Annual VEITH Symposium on Vascular and Endovascular Issues.

Alan Dietzek, M.D., Chief of Vascular Surgery and the Linda and Stephen R. Cohen Chair in Vascular Surgery at Danbury Hospital in Connecticut, presented three-year follow-up results of patients treated with the ClosureFAST catheter from a study conducted at 13 centers in the U.S. and Europe. Two-hundred sixty-seven greater saphenous veins were evaluated at the follow-up and demonstrated a 93% occlusion rate using Kaplan-Meier analysis.

In addition to clinical efficacy, the study has shown a venous clinical severity score reduction at three-year follow up, which indicates an improvement in patients' relief of symptoms, such as pain or inflammation, from the baseline score at time of treatment.
These results were consistent with those presented this month for the seven European study sites by

Professor Thomas M. Proebstle, M.D., PhD, of the Department of Dermatology, University of Mainz, Germany, and the University of Pécs, Hungary, in his presentation titled, "Three Year Follow-Up After Radiofrequency Segmental Thermal Ablation of Great Saphenous Veins." The European study was presented at the American College of Phlebology.

"These study results continue to support and strengthen clinicians' confidence in the ClosureFAST technology and its effectiveness in treating millions of venous insufficiency patients who suffer from varicose veins," said Joe Woody, President, Vascular Therapies, Covidien.

ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries.

Friday, January 28, 2011
Companies Team to Ensure Healthcare Workers on Temporary Assignments are Safeguarded from Meritless Litigation
Medical Justice, a membership-based organization dedicated to protecting physicians from meritless litigation, announced that the company will provide membership and protective services to LocumTenens.com physicians during any temporary assignment. LocumTenens.com, a free, online physician job board and full-service recruiting agency, works with healthcare facilities and government agencies that need help with their physician staffing needs. The Medical Justice program for LocumTenens.com members began January 1, 2011.

LocumTenens.com's physicians will enjoy all the benefits of a Medical Justice membership while participating in their locum tenens placements, including access to proactive services designed to deter frivolous malpractice claims, address unwarranted demands for refunds and provide proven, successful counterclaim strategies to hold proponents of frivolous suits accountable. Please call 336-691-1286 for more information.


Friday, January 28, 2011
Columbia University Names Dr. Steve Elias Director of the Columbia Vein Centers
Columbia University has named Steve Elias MD, FACS, FACPh as the Director of the Columbia Vein Centers where he will direct and develop the Vein Program at the University and other associated Columbia sites and hospitals throughout the New York and New Jersey area.

Dr. Elias will continue as Director of the Center for Vein Disease of Englewood Hospital and Medical
Center – a position he has held for 10 years – in addition to his appointment at The Columbia Vein
Centers. Under Dr. Elias’s leadership, a specialized team of Columbia physician vein specialists will use
the most technologically advanced and least invasive procedures for vein care. Patients seeking treatment
at the Columbia Vein Centers will benefit from the team approach to vein care by various specialists. All
aspects of vein disease from spider veins, varicose veins and blood clots or ulcers can be treated usually
on an outpatient basis.

Recognized as a world leader in venous disease, Steve Elias is the only doctor exclusively specializing in
vein disease on New York Magazine’s 2010 and 2009 Best Doctors List. He has also been named by
VEIN Magazine as one of the Top 25 Most Influential people globally to manage vein disease.

Pioneering the use of ClariVein, the latest technology in minimally invasive methods, Dr. Elias has helped
develop or improve most of the devices currently used to combat vein disease. Elias is also well known for
his leadership in physician education, founding the American Venous Forum’s Fellows Course in Venous
Disease and the American College of Phlebology’s Preceptorship Program, where new and practicing
physicians study contemporary treatments for venous disease.

“Columbia University is already known worldwide for excellent cardiac and vascular care, adding vein care
completes the overall management of vascular patients,” says Dr. Elias, “the commitment of Columbia
University to develop the Columbia Vein Centers under my direction adds the last piece to their world
class vascular care.”

About Dr. Steven Elias:

Dr. Steven Elias (MD FACS FACPh)Director, Centers for Vein Disease of Columbia University NY and
Englewood Hospital NJ was named by VEIN Magazine as one of the 25 most influential professionals in
vein care worldwide and Voted “Best Doctor” in 2009 and 2010 by New York Magazine. Dr. Elias lectures,
publishes, and teaches extensively about minimally invasive vein care and procedures. As Course
Director of the Annual Vascular Fellows Course in Venous Disease, he trains young vascular surgeons in
the treatment of vein problems. His clinical interests encompass all aspects of vein care: spider veins,
varicose veins, perforator and deep venous incompetence, and venous ulcers. He performs all minimally
invasive vein procedures and his work at the Center for Vein Disease includes the prevention and
treatment of DVT (Deep Venous Thrombosis). Dr. Elias is a fellowship-trained vascular surgeon and
member of the American Venous Forum, the American College of Phlebology, the Society for Clinical
Vascular Surgery, and the International Society of Cardiovascular Surgery. He is a recipient of the Dardik
Research and Education Award and The Fellows Course Education Award.
Friday, January 28, 2011
EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism
EKOS Corporation announced today the EKOS EkoSonicâ Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The EkoSonicâ System, which was originally designed and approved to dissolve blood clots in the arms and legs, now has the added indication for treating this major unmet medical need.

Robert W. Hubert, President/CEO said, "The CE mark is an important milestone for EKOS and a clear demonstration of our ongoing commitment to champion a better solution for treatment of PE. Hospitals in Europe may now begin ordering and using the EKOS device for this indication.”

Pulmonary embolism occurs in approximately 1 million patients in Europe annually (600,000 in the US), causing or contributing to 300,000 deaths each year. A PE is caused when a large blood clot obstructs the major blood vessels leading from the heart to the lungs. The victim's heart is suddenly overwhelmed with the task of pushing blood past this obstruction. Symptoms are similar to a heart attack.

About 5% of PEs are massive; resulting in rapid heart failure and shock. Without immediate therapy death can occur. A large dose of clot-dissolving drug called a thrombolytic, delivered to a vein was the only approved therapy for these patients; however, unintended bleeding, often fatal itself, is a much feared side effect.

Up to 40% of PE victims have less critical obstructions, often called submassive PE, which are currently treated with anti-coagulant medication. These medications do not remove clot; they simply prevent the clot from growing larger.

Recent, studies suggest that failure to remove these sub-massive clots may have long-term adverse events including recurrent PE, chronic pulmonary hypertension, and death. Up to 22% of these patients will die within 90 days. The EKOS EkoSonicâ System provides a new life saving therapy for these patients.

Until now, drugs were the only approved treatment. Prof. Nils Kucher from the University Hospital of Bern (Switzerland), principal investigator of the Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (ULTIMA) trial launched in 2010, emphasized, “Because the EKOS system incorporates into the catheter body small ultrasound transmitters which condition the clot to more rapidly absorb the thrombolytic drug, it can dissolve the clot faster than thrombolytic drug alone. Faster response with less thrombolytic drug means patients may recover within hours and the risk of bleeding is substantially reduced.” Tod Engelhardt, Cardiothoracic Surgeon from East Jefferson General Hospital (New Orleans) added, "I've treated 30 patients with the EKOS system. All have done remarkably well and I know we have saved lives. The patients treated were all in serious condition and within a few hours of commencing treatment were asymptomatic."

Peter Lin, vascular surgeon from Baylor College of Medicine (Houston, TX) commented, "There are frustratingly few tools available today to help the seriously ill patient with pulmonary embolism. Having now treated over 35 PE patients with the EKOS system within the past 2 years, I have adopted EKOS as our standard of care; a valuable addition to our armamentarium for pulmonary embolism."

Robert W. Hubert, President/CEO concluded, “Since 2004, the EKOS system has been cleared for use by the U.S. FDA and European authorities for use in clearing blood clots in the arms and legs. EKOS pursued CE Mark for treating PE based on receiving positive results from physicians treating these patients with the EkoSonic® system, along with several centers publishing their findings in peer reviewed journals.”

About EKOS Corporation:
EKOS Corporation pioneered the development and
clinical application of ultrasound infusion technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS EkoSonic® Endovascular System to provide faster, safer and more complete dissolution of thrombus. The EkoSonic System is FDA-cleared for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature.
Friday, January 28, 2011
Care Credit Helps Patients Accept Treatment
With trends in reimbursement continuing to widen the gap between insurance coverage and the cost of care, many vascular surgery practices have found a way to help patients manage self-pay portions by adding CareCredit Patient Payment Plans.

CareCredit offers a comprehensive range of convenient monthly payment plans that fit comfortably into a patient’s budget.

In addition to helping patients obtain treatment, practices that offer CareCredit also enjoy immediate payment, reducing their billing and A/R costs while improving cash flow.

A part of GE Capital, and the nation's leading provider of patient financing, CareCredit has helped more than 7 million patients get care and is offered in over 140,000 healthcare practices nationwide. For more information on how to increase treatment acceptance with CareCredit, call 800-300-3046, ext. 4519

Thursday, January 27, 2011
Improved Patient Care AND Marketing with CareApps Mobile Apps
OREM, UT—Position your facility a step ahead of your competitors with CareApps™ Mobile Apps for
Smart Phones. CareApps™ empowers and educates patients with portable, hand-held applications for
the iPhone, iPad and similar smart-phone devices..

CareApps™ mobile applications bridge the gap between patients and providers by offering multiple
levels of patient interaction. Apps are branded with your clinic’s logo and proprietary content and can be
integrated with your EMR to allow your patients access to a summary of their diagnostic and treatment
information. Apps are HIPAA-compliant through password protection, providing patients with the
convenience of having focused, relevant information about their customized care plan in their pocket or
purse. Your patients will appreciate instant mobile access to their individualized treatment plan, along with
answers to frequently asked questions

CareApps™ offers customizable patient care interfaces for its apps. This allows you to optimize patient
care and relationships with your facility by meeting your specific app requirements through an interface
unique to your clinic. CareApps™ apps can also be customized for any medical specialty, allowing clinics
with additional medical or cosmetic procedures to show their full range of treatment services.

Please contact CareApps™ at 866-200-3920 for more information.
Thursday, January 27, 2011
Cardiovascular Credentialing International (CCI) launched the Registered Phlebology Sonographer (RPhS) credential midyear 2010
CCI developed the RPhS credential with the support of the American College of
Phlebology. This registry level credential is available for both physicians and nonphysicians. The RPhS
examination content specifically focuses on venous ultrasound and its use to diagnose and treat patients.

Thank you to our Task Force members: Karl Hubach, MD, RVT; BB Lee, MD; Lowell Kabnick, MD;
Sergio Salles-Cunha, PhD, RVT; Barbara Schulze, RDCS, RDMS, RVT; Joseph Zygmunt, RVT; Steven
Daugherty, MD, RVT; Tracie Dauplaise, RVT; Diana Neuhardt, RVT; Nick Morrison, MD; Bill Schroedter,
RVT; Gail Size, RVT; Michael Traurig, MD, RVT; Claudia Benge, RVS, RVT; and Jeanne White, RVT.

CCI is a not-for-profit corporation established for the purpose of administering credentialing examinations
as an independent credentialing agency. CCI began credentialing cardiovascular professionals in 1968.
CCI offers eight credentials which, when earned, demonstrate that the registrant holds fundamental
knowledge in the particular cardiovascular specialty.

For more information call 1-800-326-0268
Thursday, January 27, 2011
BioMedix CEO John Romans Delivers Keynote at Shanghai Cardiology Congress
John Romans, President & CEO of BioMedix™, a leader in providing integrated medical diagnostic hardware, Health Information Technology (HIT) software and advanced web­based services, recently delivered a keynote address among global opinion leaders in China. BIT Life Sciences’ 2nd Annual International Congress of Cardiology (ICC­2010) was held December 7 – 9, 2010 in China at the Shanghai Everbright International Hotel, the largest International Conference Center in Shanghai. More than 500 participants from over 40 countries and areas attended the congress, which had the theme “Translational Medicine to Healthcare.”

Speakers at the 2nd Annual International Congress of Cardiology gave presentations in front of high
profile attendees from the academies and industries in the field of cardiology research; a dynamic global
forum of cardiologists, scientists, healthcare workers, medical executives and key opinion leaders.
Keynote speakers selected for the 2nd annual International Congress of Cardiology included well known
scientists and leaders of renowned companies in the cardiology field.

Presenting at the opening ceremony on day one of the congress, John Romans spoke on “Manufacturers
Answering the Call for Health Care Transformation – A System to Support Physicians Collaborating
to Find and Treat Peripheral Artery Disease.” The presentation addressed topics such as challenges
facing care providers in the United States, the continued rise of Peripheral Artery Disease and related
conditions worldwide, as well as customized and optimized collaborative care models as solutions to care
inefficiencies.

“This international congress was a unique opportunity for BioMedix™ to share information and ideas with
respected peers from a wide range of disciplines,” said Mr. Romans. “It is important to facilitate a global
exchange for solutions enabling the effective delivery of high quality care.”

The technologies and care models presented by John Romans have helped BioMedix™ to build centers
of excellence for patient care by providing integrated hardware, HIT software and web­based solutions.
These include the award­winning BioMedix PADnet™+ vascular diagnostic device, PADnet™ DMS 2.0
web­based vascular program solution, TRAKnet™ DPM advanced practice management and TRAKnet™
Lab and Outcomes tracking software.

About BioMedix™
BioMedix™ provides the only integrated suite of hardware, software and online services designed to cost­
effectively detect Peripheral Artery Disease (P.A.D.) and Chronic Venous Insufficiency (CVI). Vascular
specialists, primary care providers, hospitals and health systems use our products to identify these
patients. Our devices and Health Information Technology (HIT) software reduce mistakes, provide data
for sound analysis, build practice revenue and streamline reimbursement while providing a platform that
supports the continuum of care and increased quality outcomes. For more information about BioMedix™
products, call 877­-854-­0014
Thursday, January 27, 2011
Acentec’s MedInformatix’ EHR Solution Achieves ONC Meaningful Use Certification
Drummond Group Certifies Software’s Ability to Enable Eligible Professionals to Earn
Incentives Through IT for Enhanced Healthcare Quality, Patient Safety, Cost Reduction
and Improved Outcomes.

Acentec today announced that MedInformatix Electronic Health Records (EHR) is among the industry’s first to achieve certification under the U.S. Department of Health and Human Services (HHS)’ Office of National Coordinator (ONC) for Health IT’s Stage 1 meaningful use under provisions of the American Recovery and
Reinvestment Act of 2009.

Austin, Texas-based Drummond Group Inc., one of the first organizations that ONC has ordained
as an Authorized Testing and Certification Body (ATCB) of EMR products, has certified that
MedInformatix technology is capable of supporting eligible professionals (EPs) efforts to achieve
meaningful IT use goals and objectives. “Meaningful use,” under Federal Government financial
incentive programs, requires IT to enhance healthcare quality, patient safety, improve outcomes
and lower costs.

Drummond tested the MedInformatix EMR this October, approving the software and listing it on
HHS’ Certified Health IT Products Listing (CHPL).

“We’re very pleased to be offering one of the few fully certified EHR’s in the Phlebology market. In 2011,
that translates into up to $18,000 in additional revenue per provider for vein practices nationwide.”

EPs participating in Medicare and Medicaid programs and leveraging products such as
Acentec’s MedInformatix’ fully integrated EMR solution to meet ONC criteria, receive incentive payments
of as much as $44,000 per provider over 5 years when their medical facilities implement certified
technology by 2012. Total annual incentives de-escalate for practices that implement the
technology in both 2013 and 2014; professionals that fail to comply with meaningful use
provisions by 2015 face financial penalties in the form of reimbursement reductions.
Stage 1 of the meaningful use provision primarily focuses on electronic data capture, like that
facilitated by MedInformatix’ eRx module. Subsequent requirements under Stages 2 and 3 will
address additional information exchange capabilities, overall quality, safety, efficiency and
improvements in the U.S. population’s overall health.

This Complete EHR is 2011/2012 compliant and has been certified by an ONC-ATCB in accordance
with the applicable certification criteria adopted by the Secretary of Health and Human Services. This
certification does not represent an endorsement by the U.S. Department of Health and Human Services
or guarantee the receipt of incentive payments.”

About Acentec Inc.
Acentec Inc. is a leading national provider of fully integrated Electronic Health Records. We offer
turn-key solutions engineered to maximize a physician's ROI. The products have been built around
MedInformatix's 25 years of medical practice workflow expertise. Our product is designed on a single
database using Microsoft SQL. Whether the installation is a single physician who went live in 1994, a national Cardiology practice, or one of 15 other specialties we service, we accommodate their needs.
Thursday, January 27, 2011
American Board of Phlebology 2011 Exam Cycle Underway, Application Deadline February 28, 2011
Reston, VA, January, 2011 – The American Board of Phlebology opened their fourth phlebology exam cycle on October 1, 2010. Applications will be accepted until February 28, 2011, and should be submitted online at http://www.abph.net/application/default.asp. This computer-based exam will be administered electronically between April 16 and April 23, 2011. Over 400 Pearson Vue testing centers will offer the test in the United States and Canada.

To date, nearly 500 practitioners have become certified diplomates. To become an ABPh diplomate, an applicant must complete the requisite training and experience qualifications, meet the continuing medical education requisites, and pass a stringent certification examination. The initial certification period is ten years.

The American Board of Phlebology (ABPh) is an independent, non-profit organization founded in 2007 for the purpose of certifying physicians who have met a defined standard of education, training and knowledge in the field of phlebology. The American Board of Phlebology (ABPh) was established to;
Improve the standards of medical practitioners and the quality of patient care related to the treatment of venous disorders and all aspects of venous disease
Serve the public and the medical profession by establishing initial and continuing qualifications for certification as physician specialists in the practice of phlebology
Examine physician candidates for certification in the practice of phlebology
Establish educational standards for teaching and training programs in phlebology
Maintain a registry of individuals who hold certificates issued by the Board

For more information, call (703) 234-4077



Wednesday, January 26, 2011
Nominations Wanted for Jacobson Award for Physician Excellence
Lakewood, CO, January 25, 2011 – The Vascular Disease Foundation is seeking nominations for the 2011 Julius H. Jacobson II Award for Physician Excellence. The deadline for nominations is Friday, February 11.

The Julius H. Jacobson II MD Award for Physician Excellent is awarded annually by the Vascular Disease Foundation. This prestigious annual award recognizes outstanding contributions to physician education, leadership, or patient care in vascular disease. Dr. Jacobson is a pioneer in microsurgery and was the first physician to bring a microscope into the operating room. His work led to such advances as coronary artery surgery and limb reimplantation. Dr. Jacobson also developed the first microscope that allowed the surgeon and the first assistant to view the operative field simultaneously. This award is endowed through a donation from Dr. Jacobson.

Candidates for the Jacobson Award will be screened by a committee of peers independent of Dr. Jacobson. Nomination criteria are:

· Must be a licensed physician in good standing
· Has made significant contributions that have advanced the science or clinical practice for the prevention and treatment of vascular disease or who has made exceptional contributions to vascular education programs, either to health professionals or patients.
· Must be a person of recognized personal and professional integrity.
· Must not be a current member of the Board of Directors of the Vascular Disease Foundation.

This year’s recipient was Jack L. Cronenwett, MD, Professor of Surgery at Dartmouth-Hitchcock Medical Center. He ran a Vascular Surgery fellowship for many years and was one of the first program directors to initiate an integrated vascular residency where residents are recruited to spend five years in vascular residency just after graduation from medical school. He also served as President of the Association of Program Directors in Vascular Surgery and was responsible for putting together the modern curriculum in the specialty.

For more information about the Jacobson Award or to download an application, please call 888.VDF.4INFO.

The Vascular Disease Foundation is the only national organization with the sole purpose of educating the public about vascular diseases. It is the most trusted source of credible, scientific and non-biased information on vascular diseases. For more information, call 888.VDF.4INFO (888.833.4463)

###
Friday, January 07, 2011
BioMedix Releases PADnet DMS 2.0 Advanced Vascular Program Solution for Hospitals

Saint Paul, MN – BioMedix™ Vascular Solutions, Inc. announced today the release of PADnet™ Disease Management System 2.0 (PADnet™ DMS 2.0) – the enriched and redesigned evolution of its original innovative product, PDMS. The new PADnet™ DMS 2.0 features advanced reporting capabilities and a web-based interface that allows Healthcare Administrators to access and analyze network activity, accurately track referral patterns, and easily view and print reports.


PADnet™ DMS 2.0 lays the foundation for organizations to benchmark by procedure and clinician, and to make informed decisions about quality of care. It includes a turnkey collaborative care program designed to find patients with vascular disease (P.A.D./CVI) as early as possible in the community via BioMedix™ PADnet™+ in-office vascular testing devices. The seamless network connects patients with the best interventionalist for higher levels of study and intervention, leading to better care and business performance. The comprehensive suite of web-based tools implemented in the continuum of care platform enables hospitals to track clinical and financial outcomes of their vascular labs and interventional suites.


“We are extremely proud of our most recent PADnet™ Disease Management System and believe the underlying technology represents another example of our commitment to being a meaningful contributor to healthcare reform,” stated BioMedix™ CEO John Romans. “PADnet™ DMS 2.0 is already playing a critical role in enabling physicians and administrators to collaborate to offer enhanced patient care in a more cost effective and seamless manner.”


The newly designed PADnet™ DMS 2.0 Network Reporting Dashboard has advanced functionality and is the cornerstone of referral and financial data analysis for diagnostic and interventional suites. Customizable to each healthcare facility, the PADnet™ DMS 2.0 solution offers key benefits for Healthcare Administrators: searchable financial analysis for any given period, real-time program tracking and complete transparency for quantifiable program results. Advanced graphing and reporting options, such as abnormality rate, procedure type, patient history analysis, referrals to interventional suite and revenue analysis, facilitate evidence-based decision-making.


“We use the PDMS program to achieve three goals: To strengthen the relationship between our referring physicians and our vascular specialists, to create a structure around which multiple physician groups (cardiology, vascular surgery and soon radiology) participate in a program with common reporting structures, and to increase volumes, both in imaging and procedures,” said Mike Rasmussen, Executive Director, Metropolitan Cardiology Consultants Vice President, Cardiovascular Services, Mercy Hospital.


About BioMedix™


BioMedix™ Vascular Solutions, Inc. provides the only integrated suite of hardware, software and online services designed to cost-effectively detect Peripheral Arterial Disease (P.A.D.) and Chronic Venous Insufficiency (CVI). Vascular specialists, primary care providers, hospitals and health systems use our products to identify these patients. Our devices and Health Information Technology (HIT) software reduce mistakes, provide data for sound analysis, build practice revenue and streamline reimbursement while providing a platform that supports the continuum of care and increased quality outcomes. For more information about BioMedix™ products, call 877-854-0014


Search Blog

Return To Blog Home

Copyright © 2014 HealthNews.org. All rights reserved. Privacy Policy
Do not use this website as a substitute for medical care. Please consult your physician
or other medical care provider regarding any medical questions you may have.